CAR-T Cell Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of CAR-T Cell Therapy Market
The global CAR-T cell therapy market size was valued at USD 4.38 billion in 2023 and is projected to grow from USD 6.37 billion in 2024 to USD 16.35 billion by 2032, exhibiting a CAGR of 12.5% during the forecast period of 2024-2032.
The COVID-19 pandemic initially disrupted CAR-T cell remedy market sports, but the call for modern treatments persevered, which hindered CAR-T cell therapy market. Efforts have because centered on overcoming logistical demanding situations, accelerating regulatory procedures, and making sure patients get the right of entry to these lifestyle-saving treatment plans amidst the continuing disaster.
Several driving factors propel the CAR-T cell remedy market ahead. Foremost is the urgent want for powerful remedies for diverse cancers, especially for people with confined alternatives. CAR-T treatment options' fulfillment in treating certain styles of leukemia and lymphoma has spurred studies and investment in expanding their application to different cancers. Additionally, improvements in biotechnology and genetic engineering techniques have superior the development and manufacturing of CAR-T remedy plans, making them better accessible and green.
The CAR-T cell remedy market is experiencing a surge, with a projected boom rate exceeding 20% Fueled by increasing cancer diagnoses and a hit remedies for blood cancers, the marketplace is setting its attractions on new horizons leading to the expansion of CAR-T cell therapy market market share globally. Researchers are actively exploring CAR-T mobile therapy's efficacy against solid tumors, potentially increasing its reach considerably. Additionally, advancements in CAR T-cellular engineering are underway to address demanding situations like remedying patience and aspect consequences. This progressive remedy is poised to make a lasting effect at the most cancer remedy panorama.
Comprehensive Analysis of CAR-T Cell Therapy Market
Based at the drug kind and indication, the CAR-T mobile therapy marketplace has been categorized from the stop-customers’ angle as properly. Segments consist of axicabtagene ciloleucel (Yescarta) brexucabtagene autoleucel (Tecartus) ciltacabtagene autoleucel (Carvykti), idecabtagene vicleucel (Abecma) lisocabtagene maraleucel (Breyanzi), tisagenlecleucel (Kymriah), and different based totally Currently the niche is headed with the aid of axicabtagene ciloleucel, additionally called yescarta that's effective in treating non-hodgkin’s lymphoma. Segment-wise, it constitutes acute lymphoblastic leukemia, non-Hodgkin lymphoma, and a couple of myeloma, out of which non-Hodgkin lymphoma is within the dominating role stemming from a developing quantity of instances and approval from regulatory parties. Hospitals are the closest and most important customers Kite will be directly serving since the complexity of CAR-T therapies will require constant attention to CAR-T treated patients. Another advantage being realized in the management of oncology is the growth of oncology treatment centers globally, and especially in the developing world which is attributed to the enhanced choices of treatment and availability of oncology treatment centers.
The North American region led the medical devices market by benefitting a size of USD 3.01 billion in 2023 due to the growing occurrence of hematologic cancer and an upward push in each diagnosis and remedy cost.
The leading players in the CAR-T cell therapy market significantly shape its growth trajectory and establish industry benchmarks. These influential companies, such as Gilead Sciences, Inc. (U.S.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), Johnson & Johnson Services, Inc. (Janssen Global Services, LLC) (U.S.), Caribou Biosciences, Inc. (U.S.), CARsgen Therapeutics Co., Ltd (China), JW Therapeutics (Shanghai) Co., Ltd. (China), Cartesian Therapeutics, Inc. (U.S.), and Aurora Biopharma (U.S.), contribute to a competitive landscape, driving innovation and advancement in the market.
In December 2023 Max Healthcare partnered with ImmunoACT to introduce CAR-T cellular remedy in Delhi-NCR for the remedy of lymphomasand leukemias.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 12.5% from 2024-2032
Unit Value (USD billion)
Segmentation By Drug Type
Axicabtagene Ciloleucel (Yescarta)
Brexucabtagene Autoleucel (Tecartus)
Ciltacabtagene Autoleucel (Carvykti)
Idecabtagene Vicleucel (Abecma)
Lisocabtagene Maraleucel (Breyanzi)
Tisagenlecleucel (Kymriah)
Others
By Indication
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
By End-user
Hospitals
Oncology Treatment Centers
By Region
North America (By Drug Type, By Indication, By End-user, By Country)
- U.S.
- Canada
Europe (By Drug Type, By Indication, By End-user, By Country/Sub-region)
- Germany
- U.K.
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
Asia Pacific (By Drug Type, By Indication, By End-user, By Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
Rest of the World (By Drug Type, By Indication, By End-user)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.